These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 23748464)
1. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients. Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464 [TBL] [Abstract][Full Text] [Related]
3. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566 [TBL] [Abstract][Full Text] [Related]
4. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962 [TBL] [Abstract][Full Text] [Related]
5. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T; Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859 [TBL] [Abstract][Full Text] [Related]
7. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323 [TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276 [TBL] [Abstract][Full Text] [Related]
10. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744 [TBL] [Abstract][Full Text] [Related]
11. Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. Lefkowitz IB; Packer RJ; Siegel KR; Sutton LN; Schut L; Evans AE Cancer; 1990 Feb; 65(3):412-7. PubMed ID: 2153428 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B; Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663 [TBL] [Abstract][Full Text] [Related]
14. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. Geyer JR; Sposto R; Jennings M; Boyett JM; Axtell RA; Breiger D; Broxson E; Donahue B; Finlay JL; Goldwein JW; Heier LA; Johnson D; Mazewski C; Miller DC; Packer R; Puccetti D; Radcliffe J; Tao ML; Shiminski-Maher T; J Clin Oncol; 2005 Oct; 23(30):7621-31. PubMed ID: 16234523 [TBL] [Abstract][Full Text] [Related]
15. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors. Allen JC; Donahue B; DaRosso R; Nirenberg A Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1155-61. PubMed ID: 8985038 [TBL] [Abstract][Full Text] [Related]
16. Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience. Massimino M; Casanova M; Polastri D; Biassoni V; Modena P; Pecori E; Schiavello E; De Pava MV; Indini A; Rampini P; Bauer D; Catania S; Podda M; Gandola L Childs Nerv Syst; 2013 Jul; 29(7):1107-12. PubMed ID: 23595805 [TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828 [TBL] [Abstract][Full Text] [Related]
18. Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy. Al-Hader AA; Jain A; Al-Nasrallah N; Einhorn LH Am J Clin Oncol; 2015 Aug; 38(4):364-6. PubMed ID: 23799289 [TBL] [Abstract][Full Text] [Related]
19. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy. Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889 [TBL] [Abstract][Full Text] [Related]
20. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C J BUON; 2007; 12(1):41-4. PubMed ID: 17436400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]